Pharmacokinetic-pharmacodynamic model for the anticholinergic effect of glycopyrrolate

European Journal of Clinical Pharmacology

Volumn 57, Issue 2, 2001, Pages 153-158

  Penttilä, Jani ^a   Helminen, Antti ^a   Luomala, Kirsti ^a   Scheinin, Harry ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Glycopyrrolate; Heart rate; Pharmacokinetic pharmacodynamic modelling

Indexed keywords

GLYCOPYRRONIUM BROMIDE;

ADULT; ANTICHOLINERGIC EFFECT; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; HEART RATE VARIABILITY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RR INTERVAL;

ADULT; GLYCOPYRROLATE; HALF-LIFE; HEART RATE; HUMANS; MALE; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; TISSUE DISTRIBUTION;

EID: 0035035937     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100288     Document Type: Conference Paper

References (13)

1. Akaike H (1976) An information criterion (AIC). Math Sci 14:5-9
2. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ (1981) Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 213:220-222
3. Ali-Melkkila T, Kaila T, Kanto J (1989) Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. Acta Anaesthesiol Scand 33:513-517
4. Beaufort TM, Proost JH, Kuizenga K, Houwertjes MC, Kleef UW, Wierda JM (1999) Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling? J Pharmacokinet Biopharm 27:173-190
5. Colburn WA (1981) Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm 9:367-388
6. Hayano J, Sakakibara Y, Yamada A, Yamada M, Mukai S, Fujinami T, Yokoyama K, Watanabe Y, Takata K (1991) Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. Am J Cardiol 67:199-204
7. Holford NH, Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453
8. Kaila T, Ali-Melkkila T, Iisalo E, Kanto J (1990) Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. Pharmacol Toxicol 67:313-316
9. Meibohm B, Derendorf H (1997) Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 35:401-413
10. Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, Kilborn KM, Barger AC, Shannon DC, Cohen RJ, et al (1985) Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 248:H151-H153
11. Scheinin H, Helminen A, Huhtala S, Grönroos P, Bosch JA, Kuusela T, Kanto J, Kaila T (1999) Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect - integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. Ther Drug Monit 21:141-151
12. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93:1043-1065
13. Tuk B, Danhof M, Mandema JW (1997) The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. J Pharmacokinet Biopharm 25:39-62